@article{thrall_larue_yu_samulski_sanders_case_rosner_azuma_poulson_pruitt_et al._2005, title={Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy}, volume={11}, number={14}, journal={Clinical Cancer Research}, author={Thrall, D. E. and Larue, S. M. and Yu, D. H. and Samulski, T. and Sanders, L. and Case, B. and Rosner, G. and Azuma, C. and Poulson, J. and Pruitt, A. F. and et al.}, year={2005}, pages={5206–5214} }
 @article{matteucci_anyarambhatla_rosner_azuma_fisher_dewhirst_needham_thrall_2000, title={Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas}, volume={6}, number={9}, journal={Clinical Cancer Research}, author={Matteucci, M. L. and Anyarambhatla, G. and Rosner, G. and Azuma, C. and Fisher, P. E. and Dewhirst, M. W. and Needham, D. and Thrall, D. E.}, year={2000}, pages={3748–3755} }
 @article{thrall_rosner_azuma_larue_case_samulski_dewhirst_2000, title={Using units of CEM 43 degrees C T-90, local hyperthermia thermal dose can be delivered as prescribed}, volume={16}, ISSN={["1464-5157"]}, DOI={10.1080/026567300416712}, abstractNote={A randomized study was designed in dogs with spontaneous soft tissue sarcomas to gain information about the relationship between hyperthermia dose and outcome. The study compared two levels of thermal dose applied to dogs with heatable tumours, so it was necessary to deliver either a low (2-5 CEM 43°C T90) or high (20-50 CEM 43°C T90) thermal dose as precisely as possible. It was also desirable to have similar numbers of hyperthermia treatments in each thermal dose group. Identification of heatable tumours and randomization to high or low heat dose group was done during the first hyperthermia treatment. This was readily accomplished using mapping of temperatures in thermometry catheters, manual recording of thermal data, and visual inspection of raw thermal data with subsequent adjustment of the duration of the hyperthermia treatment. An analysis of precision of thermal dose delivery was conducted after approximately 50% of projected accrual had been met in a randomized phase III assessment of thermal dose effect. Fifty-four dogs were eligible for randomization; in 48 dogs the tumour was deemed heatable according to predetermined temperature criteria applied during the first heat treatment. Twenty-four dogs were randomized to the high heat dose group, and 24 to the low heat dose group. Median (range) total thermal dose for dogs in the high dose group was 43.5 CEM 43°C T90 (16.4-66.6) compared to 3.2 CEM 43°C T90 (2.1-4.6) for dogs in the low dose group. There was no overlap of thermal doses between groups. Thus, thermal dose could be delivered accurately, being within the predetermined range in 47 of the 48 dogs. Thermal dose quantified as CEM 43°C T50, however, did overlap between groups and the clinical significance of this finding will not be known until outcome data are analysed. Most dogs in both groups received five hyperthermia treatments. Median (range) treatment duration for dogs in the high dose group was 300min (147-692) compared to 111min (51-381) for dogs in the low dose group. Relatively simple but accurate methods of delivering prescribed thermal dose as described herein will aid the translation of clinical hyperthermia from the research setting into more general practice once the characteristics of the relationship between hyperthermia dose and outcome are understood.}, number={5}, journal={INTERNATIONAL JOURNAL OF HYPERTHERMIA}, author={Thrall, DE and Rosner, GL and Azuma, C and Larue, SM and Case, BC and Samulski, T and Dewhirst, MW}, year={2000}, month={Sep}, pages={415–428} }
 @article{thrall_rosner_azuma_mcentee_raleigh_1997, title={Hypoxia marker labeling in tumor biopsies: quantification of labeling variation and criteria for biopsy sectioning}, volume={44}, ISSN={["0167-8140"]}, DOI={10.1016/s0167-8140(97)01931-2}, abstractNote={The error associated with using biopsy-based methods for assessing parameters reflective of the tumor microenvironment depends on the variability in distribution of the parameter throughout the tumor and the biopsy sample. Some attention has been given to intratumoral distribution of parameters, but little attention has been given to their intrabiopsy distribution. We evaluated the intrabiopsy distribution of CCI-103F, a 2-nitroimidazole hypoxia marker.The hypoxia marker CCI-103F was studied in dogs bearing spontaneous solid tumors. Two biopsies were taken from each of seven tumors, for a total of 14 biopsies. Biopsies were serially sectioned and four to six contiguous slides from each 100-150 microm of the biopsy were used to formulate the best estimate of CCI-103F labeled area throughout the biopsy sample. One, two or four slides were then randomly selected from each biopsy and the labeled area, based on this limited sample, was compared to the estimate obtained from counting all available slides. Random sampling of slides was repeated 1000 times for each biopsy sample.CCI-103F labeling variance throughout the biopsy decreased as the estimated overall labeled area in the biopsy decreased. The error associated with estimating the overall labeled area in a biopsy from a randomly selected subset of slides decreased as the number of slides increased, and as the overall labeled area in the biopsy decreased. No minimally labeled biopsy was classified as unlabeled based on limited sampling.With regard to CCI-103F labeling, quantification of the labeled area in four randomly selected slides from a biopsy can provide, in most biopsies, an estimate of the labeled area in the biopsy within an absolute range of +/-0.05.}, number={2}, journal={RADIOTHERAPY AND ONCOLOGY}, author={Thrall, DE and Rosner, GL and Azuma, C and McEntee, MC and Raleigh, JA}, year={1997}, month={Aug}, pages={171–176} }
 @article{azuma_raleigh_thrall_1997, title={Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime}, volume={148}, ISSN={["1938-5404"]}, DOI={10.2307/3579536}, abstractNote={The longevity of pimonidazole adducts in tumors was quantified as an estimate of the lifetime of hypoxic cells. Pimonidazole was given before irradiation to 12 dogs bearing spontaneous tumors, and tumors were biopsied 24, 48 and 72 h later. Pimonidazole antigen was quantified in the biopsies using ELISA and immunohistochemistry. Pimonidazole antigen was detectable in the initial biopsy in all dogs. In 5 dogs the amount of detectable antigen decreased to less than 50% of the initial amount, in 5 other dogs the amount of detectable antigen decreased to an amount between 50 and 100% of the initial amount, and in 2 dogs the amount of antigen appeared to increase relative to the initial amount. Tumors with high initial adduct concentration were characterized by greater decreases in adduct concentration than tumors with low initial adduct concentration. Immunohistochemically, labeled cells were present in 11 of 12 tumors. The geographic area in tumor biopsies labeled immunohistochemically with pimonidazole adducts (labeled area fraction) tended to decrease over time in 6 dogs, remain stable in 4 dogs and seemingly increase in 1 dog. There was no relationship in individual tumors between the relative change in antigen concentration and the relative change in labeled area fraction. Hypoxic cells which bind pimonidazole may persist for days during fractionated radiation therapy, and the potential exists for them to exert a negative effect on the host.}, number={1}, journal={RADIATION RESEARCH}, author={Azuma, C and Raleigh, JA and Thrall, DE}, year={1997}, month={Jul}, pages={35–42} }